Lifeward and Oramed Secure Shareholder Approval for Strategic Biomedical Merger

The approval by Lifeward Ltd shareholders to proceed with a strategic partnership with Oramed Pharmaceuticals marks a transformative moment for the medical technology sector. This move, finalized on March 13, 2026, officially transitions Lifeward from its roots as a specialized developer of exoskeleton and rehabilitation robotics into a more robust, diversified biomedical entity. By combining Lifeward’s physical rehabilitation expertise with Oramed’s pharmaceutical development capabilities, the new entity aims to offer a holistic approach to patient care that spans both mechanical and chemical interventions.

The partnership is not merely a financial arrangement but a strategic alignment of two companies that have faced significant market headwinds. Lifeward, formerly known as ReWalk Robotics, has spent years navigating the complex reimbursement landscape for its wearable robotic systems. Despite achieving clinical milestones, the high cost of its devices and the slow adoption by insurance providers have historically constrained its growth. Oramed, meanwhile, has been seeking to leverage its cash reserves and proprietary oral drug delivery technology following clinical setbacks in its oral insulin program. This union allows both companies to pool resources, diversify risk, and target a broader patient demographic, particularly those with chronic conditions requiring both physical therapy and long-term medication management.

“

The approval by Lifeward Ltd shareholders to proceed with a strategic partnership with Oramed Pharmaceuticals marks a transformative moment for the medical technology sector.

Market analysts view this partnership as a defensive yet opportunistic maneuver. Just days before the shareholder vote, Lifeward announced it had regained compliance with Nasdaq’s minimum bid price requirement, a critical step that stabilized its position ahead of the merger. The timing of the shareholder approval is also significant, coming just five days before Lifeward is scheduled to report its fourth-quarter and full-year 2025 financial results on March 18, 2026. This proximity suggests that the company is eager to present a forward-looking growth narrative to investors, shifting the focus from historical losses to the potential synergies of the Oramed partnership.

The "diversified biomedical company" model is becoming increasingly attractive in an era of integrated healthcare. For patients with spinal cord injuries or stroke-related mobility issues—Lifeward’s core demographic—the integration of Oramed’s oral delivery platforms could lead to new therapeutic combinations. For instance, managing secondary complications of paralysis, such as neurogenic bladder or metabolic disorders, could be streamlined through a single provider that understands both the physical and pharmacological needs of the patient. This "one-stop-shop" approach for complex rehabilitation could significantly improve patient outcomes and reduce the administrative burden on healthcare systems.